Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post' - 2Distributed storage Answers for Information Reinforcement
- 3NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
- 4When fake data is a good thing – how synthetic data trains AI to solve real problems
- 5Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- Mom finds out she has cancer after noticing something was off while breastfeeding
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- Our favorite Space.com stories of 2025
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
